Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mir…
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021 Jan;22(1):74-85. doi:10.1038/s41590-020-00808-x. Epub 2020 Sep 30. PMID: 32999467. https://pubmed.ncbi.nlm.nih.gov/32999467/
Mallajosyula V, Ganjavi C, Chakraborty S, McSween AM, Pavlovitch-Bedzyk AJ, Wilhelmy J, Nau A, Manohar M, Nadeau KC, Davis MM. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci Immunol. 2021 Jul 1;6(61):eabg5669. doi:10.1126/sciimmunol.abg5669. PMID: 34210785; PMCID: PMC8975171. https://pubmed.ncbi.nlm.nih.gov/34210785/
Abela IA, Pasin C, Schwarzmüller M, Epp S, Sickmann ME, Schanz MM, Rusert P, Weber J, Schmutz S, Audigé A, Maliqi L, Hunziker A, Hesselman MC, Niklaus CR, Gottschalk J, Schindler E, Wepf A, Karrer U, Wolfensberger A, Rampini SK, Meyer Sauteur PM, Berger C, Huber M, Böni J, Braun DL, Marconato M, Manz MG, Frey BM, Günthard HF, Kouyos RD, Trkola A. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARSCoV-2 immunity. Nat Commun. 2021 Nov 18;12(1):6703. doi: 10.1038/s41467-021-27040-x. PMID: 34795285; PMCID: PMC8602384. https://pubmed.ncbi.nlm.nih.gov/34795285/
I know of at least 3 studies showing this:
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021 Jan;22(1):74-85. doi:10.1038/s41590-020-00808-x. Epub 2020 Sep 30. PMID: 32999467. https://pubmed.ncbi.nlm.nih.gov/32999467/
Mallajosyula V, Ganjavi C, Chakraborty S, McSween AM, Pavlovitch-Bedzyk AJ, Wilhelmy J, Nau A, Manohar M, Nadeau KC, Davis MM. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci Immunol. 2021 Jul 1;6(61):eabg5669. doi:10.1126/sciimmunol.abg5669. PMID: 34210785; PMCID: PMC8975171. https://pubmed.ncbi.nlm.nih.gov/34210785/
Abela IA, Pasin C, Schwarzmüller M, Epp S, Sickmann ME, Schanz MM, Rusert P, Weber J, Schmutz S, Audigé A, Maliqi L, Hunziker A, Hesselman MC, Niklaus CR, Gottschalk J, Schindler E, Wepf A, Karrer U, Wolfensberger A, Rampini SK, Meyer Sauteur PM, Berger C, Huber M, Böni J, Braun DL, Marconato M, Manz MG, Frey BM, Günthard HF, Kouyos RD, Trkola A. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARSCoV-2 immunity. Nat Commun. 2021 Nov 18;12(1):6703. doi: 10.1038/s41467-021-27040-x. PMID: 34795285; PMCID: PMC8602384. https://pubmed.ncbi.nlm.nih.gov/34795285/
German medical mainstream
Ärzteblatt, D. Ä. G. R. D. (2021, January 20). SARS-CoV-2: Forscher entdecken kreuzreaktive Antikörper zu. . . Deutsches Ärzteblatt. https://www.aerzteblatt.de/nachrichten/120350/SARS-CoV-2-Forscher-entdecken-kreuzreaktive-Antikoerper-zu-anderen-Coronaviren
And a new one from Canada, I forgot. I can't find it at the moment.
As always, thank you! Here is another one
The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.637651/full
Do you remember the canadian one? It was last month published, I think.